Paul M Kinsella

Paul advises on business combinations, securities offerings, and governance matters.

Matters include representing:

Wright Medical N.V. in its sale to Stryker ($5.4 billion), which closed on its original terms despite the intervening COVID-19 pandemic; merger with Tornier ($3.3 billion); $1.5 billion in convertible note and primary and secondary equity offerings; and disclosure and governance matters

CIRCOR in its defense against an unsolicited bid and in a proxy contest with an activist investor

TESARO in its sale to GSK ($5.1 billion)

NxStage in its sale to Fresenius ($2.0 billion)

Pfizer in its acquisitions of Medivation ($14 billion), in which Pfizer prevailed in an auction triggered by an unsolicited bid by another pharmaceutical company, and Hospira ($17 billion)

Novavax in $1.5 billion in equity and convertible note offerings and disclosure and governance matters

Shire in its acquisitions of Baxalta ($32 billion), which commenced with an unsolicited public proposal shortly following Baxalta’s spin-off from Baxter, and Dyax ($5.9 billion)

Synageva in its sale to Alexion ($8.9 billion); $2.0 billion in equity offerings; and disclosure and governance matters

The lead underwriters in a $6.7 billion secondary offering of Regeneron common stock and a $2.0 billion Regeneron investment grade debt offering